A new annual injection aimed at preventing HIV has successfully passed a crucial early safety trial.

This medication, known as lenacapavir, works by inhibiting the virus’s replication process. Unlike daily PrEP pills, lenacapavir is administered just once a year, slowly releasing into the bloodstream to ensure continuous protection.

Clinical trials revealed that the drug maintained effective levels in the body for over 56 weeks. Most reported side effects were mild, with temporary discomfort at the injection site being the most common.

In the study, 40 HIV-negative participants received a single injection, and no major safety concerns were observed. These results have sparked excitement among HIV advocacy groups, providing hope for a more convenient prevention option.

The research findings were published in The Lancet medical journal.